163 related articles for article (PubMed ID: 10340403)
1. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease.
Peters AM; Kohfink B; Martin H; Griesinger F; Wörmann B; Gahr M; Roesler J
Exp Hematol; 1999 May; 27(5):868-74. PubMed ID: 10340403
[TBL] [Abstract][Full Text] [Related]
2. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
3. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
4. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency.
Ströbel P; Nanan R; Gattenlöhner S; Müller-Deubert S; Müller-Hermelink HK; Kreth HW; Marx A
Am J Surg Pathol; 1999 Jul; 23(7):829-37. PubMed ID: 10403307
[TBL] [Abstract][Full Text] [Related]
5. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.
Straus SE; Jaffe ES; Puck JM; Dale JK; Elkon KB; Rösen-Wolff A; Peters AM; Sneller MC; Hallahan CW; Wang J; Fischer RE; Jackson CE; Lin AY; Bäumler C; Siegert E; Marx A; Vaishnaw AK; Grodzicky T; Fleisher TA; Lenardo MJ
Blood; 2001 Jul; 98(1):194-200. PubMed ID: 11418480
[TBL] [Abstract][Full Text] [Related]
6. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
Nagata S
J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
[TBL] [Abstract][Full Text] [Related]
7. Pathological findings in human autoimmune lymphoproliferative syndrome.
Lim MS; Straus SE; Dale JK; Fleisher TA; Stetler-Stevenson M; Strober W; Sneller MC; Puck JM; Lenardo MJ; Elenitoba-Johnson KS; Lin AY; Raffeld M; Jaffe ES
Am J Pathol; 1998 Nov; 153(5):1541-50. PubMed ID: 9811346
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune lymphoproliferative syndrome.
Sneller MC; Dale JK; Straus SE
Curr Opin Rheumatol; 2003 Jul; 15(4):417-21. PubMed ID: 12819469
[TBL] [Abstract][Full Text] [Related]
9. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.
Infante AJ; Britton HA; DeNapoli T; Middelton LA; Lenardo MJ; Jackson CE; Wang J; Fleisher T; Straus SE; Puck JM
J Pediatr; 1998 Nov; 133(5):629-33. PubMed ID: 9821419
[TBL] [Abstract][Full Text] [Related]
10. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
Fisher GH; Rosenberg FJ; Straus SE; Dale JK; Middleton LA; Lin AY; Strober W; Lenardo MJ; Puck JM
Cell; 1995 Jun; 81(6):935-46. PubMed ID: 7540117
[TBL] [Abstract][Full Text] [Related]
11. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis.
Pensati L; Costanzo A; Ianni A; Accapezzato D; Iorio R; Natoli G; Nisini R; Almerighi C; Balsano C; Vajro P; Vegnente A; Levrero M
Gastroenterology; 1997 Oct; 113(4):1384-9. PubMed ID: 9322534
[TBL] [Abstract][Full Text] [Related]
12. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations.
Rieux-Laucat F; Blachère S; Danielan S; De Villartay JP; Oleastro M; Solary E; Bader-Meunier B; Arkwright P; Pondaré C; Bernaudin F; Chapel H; Nielsen S; Berrah M; Fischer A; Le Deist F
Blood; 1999 Oct; 94(8):2575-82. PubMed ID: 10515860
[TBL] [Abstract][Full Text] [Related]
13. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.
Fleisher TA; Straus SE; Bleesing JJ
Curr Allergy Asthma Rep; 2001 Nov; 1(6):534-40. PubMed ID: 11895618
[TBL] [Abstract][Full Text] [Related]
14. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis.
Fleisher TA
Immunol Res; 2008; 40(1):87-92. PubMed ID: 18193364
[TBL] [Abstract][Full Text] [Related]
15. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.
Martin DA; Zheng L; Siegel RM; Huang B; Fisher GH; Wang J; Jackson CE; Puck JM; Dale J; Straus SE; Peter ME; Krammer PH; Fesik S; Lenardo MJ
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4552-7. PubMed ID: 10200300
[TBL] [Abstract][Full Text] [Related]
16. [The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases].
Beltinger C; Böhler T; Schrappe M; Ludwig WD; Debatin KM
Klin Padiatr; 1998; 210(4):153-8. PubMed ID: 9743945
[TBL] [Abstract][Full Text] [Related]
17. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations.
Vaishnaw AK; Orlinick JR; Chu JL; Krammer PH; Chao MV; Elkon KB
J Clin Invest; 1999 Feb; 103(3):355-63. PubMed ID: 9927496
[TBL] [Abstract][Full Text] [Related]
18. Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele.
Roesler J; Izquierdo JM; Ryser M; Rösen-Wolff A; Gahr M; Valcarcel J; Lenardo MJ; Zheng L
Blood; 2005 Sep; 106(5):1652-9. PubMed ID: 15870181
[TBL] [Abstract][Full Text] [Related]
19. Increased spontaneous in vitro apoptosis in double negative T cells of humans with a fas/apo-1 mutation.
Haas JP; Grunke M; Frank C; Kolowos W; Dirnecker D; Leipold G; Hieronymus T; Lorenz HM; Herrmann M
Cell Death Differ; 1998 Sep; 5(9):751-7. PubMed ID: 10200534
[TBL] [Abstract][Full Text] [Related]
20. A new disorder of lymphocyte apoptosis: combination of autoimmunity, infectious lymphadenopathy, double negative T cells, and impaired activation-induced cell death.
Hundt M; Posovszky C; Schmidt RE
Immunobiology; 2002 Dec; 206(5):514-8. PubMed ID: 12607726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
